Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent ...

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event ...

BioNTech's pipeline setback shouldn't have completely surprised investors. The independent Data Safety Monitoring Board (DSMB) for the Phase 2 study of autogene cevumeran concluded in October 2025 ...

大家久等了，有事情忙了几天，两三天以前就把v0.4整好了，忙忘了，忘了更新。 NS OpenBor4.0 v0.4更新 1.继续优化快打旋风LNS的加载速度。 2.加入对米之家快打旋风LNS系列分卷游戏的适配。 3.修正 ...

Assetto Corsa Rally’s V0.6 update is set to include a new photo mode, private lobbies and the introduction of custom liveries.

BioNTech has terminated a phase 2 trial of autogene cevumeran in ctDNA-positive, resected colorectal cancer after a DSMB found an overall survival imbalance. BioNTech has decided to terminate the ...

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...

Intismeran autogene plus pembrolizumab significantly improved RFS and DMFS compared with standard of care, with overall survival monitoring ongoing. Topline data were announced from the phase 3 ...

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant ...

Shares of Merck (MRK) and Moderna (MRNA) spiked in the premarket on Wednesday after the companies said that their jointly developed messenger RNA-based cancer therapy, intismeran autogene, succeeded ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...